Baseline Chronic Kidney Disease and Ischemic Method of Partial Nephrectomy Are Important Factors for the Short- and Long-Term Deterioration in Renal Function for Renal Cell Carcinoma Staged T1-T2: A Retrospective Single Center Study
Table 1
Patient baseline demographics ( = 215).
Parameter
Median (range)
Percentage or SD
Age (years)
55 (24–78)
Gender (male/female)
154/61
71.6/28.4
BMI (kg/m2)
24.7 (16.6–39.8)
Underlying disease
Diabetes
32
14.9
Hypertension
89
41.4
Hypercholesterolemia
9
4.2
Ischemic heart disease
5
2.3
Anticoagulation therapy history
8
3.7
Aspirin therapy
21
9.8
ASA score 0/1/2
112/95/8
52.1/44.2/3.7
ECOG 0/1/2
143/70/2
66.5/32.6/0.9
Smoking
121
56.3
Smoking volume (PY)
8 (0–87)
Follow-up duration (mo)
43 (12–134)
Preoperative laboratory findings
Hemoglobin
14 (8.6–17.5)
Albumin
4.6 (3.6–5.9)
Calcium
9.4 (8.3–10.9)
Total Cholesterol
185.5 (97–335)
De Ritis ratio (AST/APT)
1.1 (0.3–3.1)
Creatinine
1.0 (0.6–1.8)
Estimated GFR
69.7 (37.3–103.4)
Preoperative PADUA score
8.0 (5–12)
Tumor number
2.4 (0.3–16)
Low/intermediate/high
67/86/62
31.2/40.0/28.8
Longitudinal: Inf/interpolar/med/mid/sup
60/42/3/60/50
27.9/19.5/1.4/27.9/23.3
RENAL score
7 (3–18)
Ant/post
107/108
49.8/50.2
Disease category
Preoperative
CKD RCC
46
21.4
Non-CKD RCC
145
67.4
Benign renal mass
24
11.2
Operative method
Laparoscopy
33
15.4
Open
182
84.6
Pathologic T stage
T1
193
89.8
T2
22
10.2
Fuhrman grade
1
20
9.3
2
131
60.9
3
43
20.0
4
2
1.4
Unknown
19
8.8
Margin positive
30
14.0
Safety resection margin (mm)
2.0 (1.0–9.0)
Ischemic method warm/cold/no
131/42/42
60.9/19.5/19.5
Ischemic time (min)
21 (0–70)
Number of clamping vessels
2 (1–4)
Tumor diameter (cm)
2.0 (0.5–2.2)
Postoperative 5-year follow-up
Creatinine
1.6 (0.6–2.2)
eGFR
78.1 (29–118.8)
Histology
Clear cell, pure
167
77.7
Papillary
16
7.4
Chromophobe
8
3.7
Benign renal mass
24
11.2
Recurrence
1
0.5
Time to recurrence
52.1 (4.8–48.8)
SD, standard deviation; MSKCC, Memorial Sloane Kettering Cancer Center; LN, lymph node; F/U, follow-up; PD, progressive disease; SD, stable disease; PR, partial response; CR, complete response; RECIST, Response Evaluation Criteria In Solid Tumors.